An open-label randomized controlled trial on interferon β-1b and hydroxychloroquine combination versus hydroxychloroquine alone, as treatment for COVID-19 infection
Grant Data
Project Title
An open-label randomized controlled trial on interferon β-1b and hydroxychloroquine combination versus hydroxychloroquine alone, as treatment for COVID-19 infection
Principal Investigator
Professor Hung, Fan Ngai Ivan
(Principal Investigator (PI))
Co-Investigator(s)
Professor To Kelvin Kai Wang
(Co-Investigator)
Professor Yuen Kwok Yung
(Co-Investigator)
Dr Chan Kwok Hung
(Co-Investigator)
Duration
24
Start Date
2020-07-01
Amount
2999040
Conference Title
An open-label randomized controlled trial on interferon β-1b and hydroxychloroquine combination versus hydroxychloroquine alone, as treatment for COVID-19 infection
Presentation Title
Keywords
hydroxychloroquine, interferon, randomized controlled
Discipline
Others - Medicine, Dentistry and Health
HKU Project Code
COVID190125
Grant Type
Commissioned Research on the Novel Coronavirus Disease (COVID-19)
Funding Year
2019
Status
On-going
Objectives
The novel coronavirus (SARS-CoV-2) is a single-stranded RNA coronavirus. The virus was first isolated from patients presented with pneumonia in Wuhan in December 2019. Sequences of the Wuhan betacoronavirus show similarities to betacoronaviruses found in bats, sharing a common ancestor with the 2003 SARS coronavirus (SARS-CoV) and the bat coronavirus. Similar to SARS-CoV, it is a member of Beta-CoV lineage B.